Spots Global Cancer Trial Database for Study of GNX102 in Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of GNX102 in Patients With Advanced Solid Tumors
Official Title: A Phase I Study of GNX102 in Patients With Advanced Solid Tumors
Study ID: NCT04250597
Study Description
Brief Summary: GNX102 is a humanized monoclonal antibody (mAb), an engineered biotechnology product, developed by GlycoNex that targets certain cancer cells by binding with high affinity to specific structures on cancer cells. Specifically, GNX102 binds to novel glycan structures caused by glycosylation changes in tumors. Patients with epithelial origin cancers that have a likelihood of GNX102 targeted antigen expression based on previous studies, including colorectal, hepatocellular, non-small cell lung, gastric, breast, pancreatic, cutaneous, acral, or mucosal melanoma, esophageal, prostate, and epithelial uterine cancers, can be screened for enrollment in the study.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Hoag Cancer Center (USC), Newport Beach, California, United States
Regions Cancer Care Center, Saint Paul, Minnesota, United States
Providence Cancer Institute Earle A. Chiles Research Institute, Portland, Oregon, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
China Medical University Hospital (CMUH), Taichung, , Taiwan
National Cheng Kung University Hospital (NCKUH), Tainan, , Taiwan
Contact Details
Name: Mei-Chun Yang, PhD
Affiliation: President, GlycoNex, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
